The National AIDS Commission (NAC) has raised serious concern over a steady increase in HIV cases across Liberia, revealing that the number of people living with the virus has climbed from 34,000 in ...
Health experts are alarmed as Republicans degrade the country’s pivotal HIV programs — and break promises made during Trump’s ...
This story originally appeared in the Tuesday, Nov. 20, 2007 edition of the. Per California Education Code 59134, ...
Celebrating the stories of PATF and Allies FEATURING: Kathi Boyle, Stuart Fisk, Tammy Frech, DJ Stemmler & Pam Vingle, Nachum Golan & Steve Hough, Alan Jones, ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Despite Uganda's steady progress in reducing HIV infections and AIDS-related deaths, men remain disproportionately affected due to low uptake of antiretroviral treatment (ARVs), the Uganda AIDS ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
ICA to screen Independent documentary amid unprecedented cuts to global HIV/AIDs response - To mark World AIDS Day, the Institute for Contemporary Arts will screen our film tackling the collapse of US ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback